Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: A case report

Japanese Journal of Clinical Oncology

Volumn 31, Issue 8, 2001, Pages 403-406

  Osada, Takuya ^a   Fujimaki, Takamitsu ^a   Takamizawa, Masaru ^a   Tsuno, Nelson H ^a   Kirino, Takaaki ^a   Shibata, Yoichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dendritic cell; Immunotherapy; Intracranial germ cell tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; METRIZAMIDE; STEROID;

ADULT; ANAMNESIS; ARTICLE; BRAIN TUMOR; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DENDRITIC CELL; DENSITY GRADIENT CENTRIFUGATION; DRUG MEGADOSE; GERM CELL TUMOR; HISTOLOGY; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKAPHERESIS; MALE; MALIGNANT NEOPLASTIC DISEASE; PARENCHYMA; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 0034797389     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye076     Document Type: Article

References (22)

1. Intracranial germ-cell tumors: Natural history and pathogenesis
2. Report of brain tumor registry of Japan (1969-1993)
3. Primary intracranial germ cell tumors: A clinical analysis of 153 histologically verified cases
4. Chemotherapy for brain tumors
5. Combined chemotherapy and radiation therapy for central nervous system germ cell tumors: Preliminary results of a phase II study of the Japanese Pediatric Brain Tumor Study Group
6. Dendritic cells and the control of immunity
7. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells
8. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
9. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
10. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors
11. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alpha
12. Spontaneous regression of a residual pineal tumor after resection of a cerebellar vermian germinoma
13. Primary intracranial germ cell tumors
14. Tumor-infiltrating lymphocytes and histocompatibility antigens in primary intracranial germinomas
15. Intratumoral LAK cell and interleukin 2 therapy of human gliomas
16. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
17. Adoptive immunotherapy with LAK cells and interleukin-2 in the treatment of recurrent malignant gliomas
18. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
19. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
20. Bone marrow-derived dendritic cells pulsed with tumor homogenate induced immunity against syngeneic intracerebral glioma
21. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow
22. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo